AFP and hepatocellular carcinoma: Zhu et al. proposed an AFP cutoff ≥ 75% decrease and ≤10% increase from baseline at 6 weeks as a potential biomarker for the efficacy of atezo/bev among patients with HCC, especially HBV-related etiology [127].